Oculis Holding AG (OCS) had a rough Monday. The biotech company's stock cratered 37% after it announced that its Phase 3 DIAMOND trials for OCS-01 eye drops—designed to treat diabetic macular edema (DME)—didn't hit their primary goal.
The neuro-ophthalmology and ophthalmology-focused company reported that the primary endpoint of the DIAMOND trials was not met, which has led to the decision not to pursue an FDA regulatory filing for OCS-01 in diabetic macular edema.
Even though the drug showed a well-tolerated safety profile, the lack of significant improvement in visual acuity spooked investors. It's a classic case of a treatment that did something—reduced retinal thickness—but not the thing that matters most to patients: seeing better.
Riad Sherif, CEO of Oculis, put it plainly: “We are naturally disappointed that the substantial and sustained reduction in retinal thickness observed across both trials didn’t translate into BCVA improvement at week 52.”
He added that the company will now “strategically focus resources on advancing our late-stage portfolio, including the Privosegtor platform, starting with the PIONEER program for Privosegtor in optic neuropathies, and the PREDICT-1 trial for Licaminlimab to drive precision medicine in dry eye disease.”
So Oculis is pivoting. The OCS-01 DME program is effectively dead, but the company has other irons in the fire. The Privosegtor platform targets optic neuropathies, and the PREDICT-1 trial is aimed at dry eye disease. Investors will be watching closely to see if those programs can deliver better news.
